SCHEMBL3412331

SCHEMBL3412331

COc1ccc(CNc2ncnc3c2ncn3C2CCCO2)cc1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.66
▸ RAB9A P51151 1/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.66
▸ CYP1A2 P05177 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ PAX8 Q06710 1/20 0.50
▸ CCNB2 O95067 1/20 0.50
▸ CDK1 P06493 1/20 0.50
▸ CCNB1 P14635 1/20 0.50
▸ CCNB3 Q8WWL7 1/20 0.50
▸ CYP2C19 P33261 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ APEX1 P27695 1/20 0.48
▸ PI4KA P42356 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3414947 0.97 NPC1 (0.70) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL2002143 0.93 NPC1 (0.64) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL2390228 0.88 NPC1 (0.72) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL3408388 0.87 NPC1 (0.68) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL30409327 0.86 NPC1 (0.49) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL2391298 0.86 NPC1 (0.70) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL2389430 0.86 ADORA3 (0.59) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL3414562 0.86 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL2391745 0.85 NPC1 (0.77) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL2389414 0.84 NPC1 (0.59) NPC1RAB9ASMN1; SMN2CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2043630-B1 6, 9-DISUBSTITUTED PURINE DERIVATIVES FOR COSMETIC USE INST OF EX BOTANY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2016-09-07 — — EP disclosed
US-20100234401-A1 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin SZUCOVA LUCIE 2010-09-16 — — US disclosed
US-20080009508-A1 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2008-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234401-A1 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin UNG, P2RY6, MPG NPC1 3196/4885RAB9A 1395/4885SMN1; SMN2 3167/4885
US-20080009508-A1 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin UNG, P2RY6, MPG NPC1 3196/4885RAB9A 1395/4885SMN1; SMN2 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback